- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03963661
Investigating Usability of c-SIGHT in the Homes of Brain Injury Survivors (c-SIGHT)
Investigating a Portable Patient-led Virtual Reality Platform for Assessment and Rehabilitation of Hemispatial Neglect: a Usability Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stephanie Rossit, Ph.D
- Phone Number: +44 (0)160359 1674
- Email: s.rossit@uea.ac.uk
Study Contact Backup
- Name: Valerie Pomeroy, Ph.D
- Phone Number: +44 (0)1603 59 1668
- Email: v.pomeroy@uea.ac.uk
Study Locations
-
-
Norfolk
-
Norwich, Norfolk, United Kingdom, NR4 7TJ
- Recruiting
- University of East Anglia
-
Contact:
- Stephanie Rossit, PhD
-
Principal Investigator:
- Stephanie Rossit
-
Sub-Investigator:
- Valerie Pomeroy
-
Sub-Investigator:
- Amy Jolly
-
Sub-Investigator:
- Helen Morse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- +18
- suffered brain injury
- have TV with around 2 meters in front of it to be able to run the therapy
- live in the Norfolk, Suffolk, Essex or Cambridgeshire (UK)
- no other pre-existing neurological disorders (such as dementia)
- no language impairment (able to follow 1-stage command)
- mental capacity to consent
- no known learning disability
- no major psychiatric illness
- no history of substance abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: c-SIGHT
SIGHT requires participants to grasp and lift rods with their less impaired arm.
|
C-SIGHT will be self-administered at people's homes.
c-SIGHT is a computerized therapy administered via people's television.
The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop.
A small motion-tracking camera monitors rod lifts during therapy sessions.
People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days.
The first day of therapy will be performed with a therapist there for training purposes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Behavioral Inattention Test (BIT) conventional sub tests
Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Standardized measure of spatial inattention
|
Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Line bisection Test
Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Test for spatial inattention which measures spatial biases when marking middle of 10 20mm lines.
Bisection error bigger that 6mm is considered evidence of spatial inattention.
|
Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Broken Hearts test from Oxford Cognitive Screening (paper version)
Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Standardized measure of spatial inattention
|
Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Computerized extrapersonal neglect test (CENT)
Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Computerized test measuring ego and allocentric neglect sub types in extra personal space via television screen
|
Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Catherine Bergego Scale
Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Standardized checklist to detect presence and degree of unilateral neglect during observation of everyday life situations. The scale also measures self-awareness of behavioral neglect (anosognosia). The CBS uses a 4-point rating scale to indicate the severity of neglect for each item: 0 = no neglect
This results in a total score out of 30. Azouvi et al. (2002, 2003) have reported arbitrary ratings of neglect severity according to total scores: 0 = No behavioral neglect 1-10 = Mild behavioral neglect 11-20 = Moderate behavioral neglect 21-30 = Severe behavioral neglect |
Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Pinch and grip force task (dynamometer)
Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Measures upper limb function
|
Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Caregiver Burden Scale
Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
To assess perceived burden among people caring for others with disabilities. There are 22 items in which the carer rates perceived burden from 0 (never) to 4 (nearly always). A total score of 0 to 20 = little or no burden; 21 to 40 = mild to moderate burden; 41 to 60 = moderate to severe burden; 61 to 88 = severe burden. |
Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Stroke Specific Quality of Life Scale (SS-QOL)
Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
A patient-centered outcome measure intended to provide an assessment of health-related quality of life (HRQOL) specific to patients with stroke.
Patients must respond to each question of the SS-QOL with reference to the past week.
It is a self-report scale containing 49 items in 12 domains.
Items are rated on a 5-point Likert scale.
Higher scores indicate better functioning.
The SS-QOL yields both domain scores and an overall SS-QOL summary score.
The domain scores are unweighted averages of the associated items while the summary score is an unweighted average of all twelve domain scores.
|
Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
System Usability Scale
Time Frame: immediately after 7 days of therapy (T2)
|
To assess usability of devices and applications. Participants are asked to score the following 10 items with one of five responses that range from Strongly Agree to Strongly disagree. The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. Though the scores are 0-100, these are not percentages and should be considered only in terms of their percentile ranking. Based on research, a SUS score above a 68 would be considered above average and anything below 68 is below average. |
immediately after 7 days of therapy (T2)
|
Semi-structured interview at end of study with carer and stroke survivor
Time Frame: immediately after 7 days of therapy (T2)
|
To assess usability (qualitative data)
|
immediately after 7 days of therapy (T2)
|
WAIS Digit span (control measure)
Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Digit span from WAIS (forward, backward and sequential) is used as a control task
|
Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2)
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R206721
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey